claim: an alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in human and nonhuman primates
evidence_1: these data suggest that a 250-μg prime-only dose or a 50-μg prime/boost immunization with the lion/reprna-cov2s vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease.